# Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer (PULSE Study)

> **NCT07744698** · PHASE4 · RECRUITING · sponsor: **Anhui Provincial Cancer Hospital** · enrollment: 107 (estimated)

## Conditions studied

- Squamous Non-Small Cell Lung Cancer sqNSCLC
- Extensive-stage Small Cell Lung Cancer (ES-SCLC)

## Interventions

- **DRUG:** Paclitaxel Oral Solution
- **DRUG:** PD-1/PD-L1 inhibitor (eg. Tislelizumab)

## Key facts

- **NCT ID:** NCT07744698
- **Lead sponsor:** Anhui Provincial Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-24
- **Primary completion:** 2029-06
- **Final completion:** 2029-06
- **Target enrollment:** 107 (ESTIMATED)
- **Last updated:** 2026-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07744698

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07744698, "Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer (PULSE Study)". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07744698. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*